| Swiss Cancer Centre - Leman | |
| Native Name: | Centre suisse du cancer - Arc lémanique |
| Established: | 2016 |
| Research Field: | Oncology |
| Director: | Prof. George Coukos, Prof. Douglas Hanahan, Prof. Pierre-Yves Dietrich |
| Address: | Rue du Bugnon 1011 Lausanne |
| City: | Lausanne |
| Country: | Switzerland |
| Affiliations: | CHUV, UNIL, EPFL, University Hospitals of Geneva (HUG) and University of Geneva (UNIGE). |
The Swiss Cancer Center - Leman (SCCL) is an alliance against cancer forged between several academic and clinical institutions: the University Hospital of Lausnne (CHUV), the University Hospitals of Geneva (HUG), the University of Lausanne, the University of Geneva and the Swiss Federal Institute of Technology Lausanne (EPFL), as well as privileged partners (see below).[1]
This alliance brings together, under a united and regional identity, all the specialists involved in the path from bench to bedside. Focusing their efforts on emerging fields within oncology, the partner institutions intend to develop innovative strategies such as immunotherapy and precision oncology to achieve personalized and predictive medical strategies that will ultimately revolutionize patient care.[2]
The SCCL conducts its research in a network of laboratories located within its constituent institutions.
The SCCL Executive Committee is composed of the senior directors in oncology of its partner institutions:
The Agora, the flagship building of the Swiss Cancer Centre - Leman (SCCL), embodies and puts into the practice the central vision of the SCCL has for cancer science and medicine. A FLASH radiotherapy device for treatment of cancers resistant to conventional treatments is developed together with CERN and THERYQ (Alcen Group) and will be installed at the CHUV. The first clinical trials are planned for 2025.[3] [4]
In 2016, the University Hospital of Lausanne inaugurated a cell production laboratory for cancer immunotherapy on the Biopôle campus (Épalinges).[5]